We are proposing the establishment of a specialized chemistry center, the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, to expedite the discovery and development of high quality probe compounds which will significantly impact the goals of the MLPCN Research Network. Building on the infrastructure, resources and broad drug discovery (hit-to-lead-to-proof of concept-to-clinic) experience within the Lindsley Technology Enabled Synthesis (TES) Lab and the Conn Lab, we are poised to support probe development projects in collaboration with external Specialty Screening and Comprehensive Centers in the MLPCN Network. Due to our state-of-the-art technology platform for high-throughput medicinal chemistry and our M.S. and Ph.D. level staff chemists, our proposed center will be capable of supporting five (5) probe development projects, with internal or external centers, in parallel (~20 probe development programs/year) and require less than three months to develop probes and advanced molecular tools for in vitro and/or in vivo proof of concept experiments. The proposed Vanderbilt Specialized Chemistry Center for Accelerated Probe Development is unique from other centers in that the PI has eight years hit-to-lead-to-proof of concept experience in the pharmaceutical industry and has built a fully equipped high-throughput synthesis and purification lab, at the industry standard, within Vanderbilt which allows minimal human resources to develop probe compounds with expedited timelines. Our initial goal will be to deliver probe compounds that meet or exceed MPLCN guidelines and/or meet specific requirements for a probe of the investigator that initiated the screen. When aligned with NIH/NIMH and MLPCN goals, we will use a portion of our MLPCN and internal resources in the Lindsley and Conn Labs (synthesis/medicinal chemistry, pharmacology, DMPK and adiochemistry) in Center-Driven Research Projects to further refine and develop probes for therapeutically relevant targets to ensure in vivo proof of concept experiments can be performed to provide 'quick kills'or validate targets as potential therapeutic agents for unmet medical needs. Finally, we will offer training sabbaticals to other chemists within the MLPCN to learn parallel synthesis techniques and library design strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54MH084659-05
Application #
8337390
Study Section
Special Emphasis Panel (ZRG1-IFCN-K (52))
Program Officer
Brady, Linda S
Project Start
2008-09-01
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
5
Fiscal Year
2012
Total Cost
$3,000,000
Indirect Cost
$1,010,193
Name
Vanderbilt University Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Kurata, Haruto; Gentry, Patrick R; Kokubo, Masaya et al. (2015) Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges. Bioorg Med Chem Lett 25:690-4
Pancani, Tristano; Bolarinwa, Caroline; Smith, Yoland et al. (2014) M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. ACS Chem Neurosci 5:318-24
Jones, Carrie K; Sheffler, Douglas J; Williams, Richard et al. (2014) Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Bioorg Med Chem Lett 24:1067-70
O'Reilly, Matthew C; Scott, Sarah A; Brown, H Alex et al. (2014) Further evaluation of novel structural modifications to scaffolds that engender PLD isoform selective inhibition. Bioorg Med Chem Lett 24:5553-7
Gentry, Patrick R; Kokubo, Masaya; Bridges, Thomas M et al. (2014) Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. ChemMedChem 9:1677-82
Bruntz, Ronald C; Taylor, Harry E; Lindsley, Craig W et al. (2014) Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem 289:600-16
Oguin 3rd, Thomas H; Sharma, Shalini; Stuart, Amanda D et al. (2014) Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibition. J Biol Chem 289:25405-17
Scott, Sarah A; Mathews, Thomas P; Ivanova, Pavlina T et al. (2014) Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta 1841:1060-84
Wenthur, Cody J; Morrison, Ryan D; Daniels, J Scott et al. (2014) Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu(2)/mGlu(3) NAMs. Bioorg Med Chem Lett 24:2693-8
Gregory, Karen J; Nguyen, Elizabeth D; Malosh, Chrysa et al. (2014) Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. ACS Chem Neurosci 5:282-95

Showing the most recent 10 out of 74 publications